CORXEL Pharmaceuticals Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 45

Employees

  • Latest Deal Type
  • Series D1

  • Latest Deal Amount
  • $287M

  • Investors
  • 15

CORXEL Pharmaceuticals General Information

Description

Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. The company offers first-class treatments to Chinese cardiovascular and ophthalmology patients and treats patients suffering from serious life-threatening health diseases, thereby enabling biotechnology companies to respond to unmet medical needs in the fields of cardiovascular and ophthalmology diseases.

Contact Information

Website
www.corxelbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 22nd Floor, Jinjiang Cultural Plaza
  • Number 1225 Nanjing West Road, Jing'an District
  • Shanghai, 200040
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 22nd Floor, Jinjiang Cultural Plaza
  • Number 1225 Nanjing West Road, Jing'an District
  • Shanghai, 200040
  • China
+86 021

CORXEL Pharmaceuticals Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CORXEL Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D1) 22-Jan-2026 $287M Completed Generating Revenue
3. Later Stage VC (Series D1) 19-Sep-2024 Completed Generating Revenue
2. Later Stage VC (Series D) 06-Jan-2024 $162M $162M Completed Generating Revenue
1. Early Stage VC (Series B) 13-Jul-2021 Completed Generating Revenue
To view CORXEL Pharmaceuticals’s complete valuation and funding history, request access »

CORXEL Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomy
Drug Discovery
Shanghai, China
45 As of 2019

Guangzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CORXEL Pharmaceuticals Competitors (1)

One of CORXEL Pharmaceuticals’s competitors is Zhiyi Biotechnology, a Venture Capital-Backed company based in Guangzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zhiyi Biotechnology Venture Capital-Backed Guangzhou, China
You’re viewing 1 of 1 competitors. Get the full list »

CORXEL Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CORXEL Pharmaceuticals Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
HBM Healthcare Investments Venture Capital Minority
Hengdian Group Capital (HgC) Corporate Venture Capital Minority
Invus (Private Equity) PE/Buyout Minority
New Enterprise Associates Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

CORXEL Pharmaceuticals Investments & Acquisitions (3)

CORXEL Pharmaceuticals’s most recent deal was a Merger/Acquisition with Amanat Acquisition for . The deal was made on 25-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amanat Acquisition 25-Oct-2026 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Biogen (BIIB131 Drug) 11-Jan-2024 Corporate Asset Purchase Buildings and Property
PhaseBio Pharmaceuticals (Global Rights to PB6440) 03-Feb-2023 Corporate Asset Purchase Buildings and Property
To view CORXEL Pharmaceuticals’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

CORXEL Pharmaceuticals FAQs

  • When was CORXEL Pharmaceuticals founded?

    CORXEL Pharmaceuticals was founded in 2019.

  • Where is CORXEL Pharmaceuticals headquartered?

    CORXEL Pharmaceuticals is headquartered in Shanghai, China.

  • What is the size of CORXEL Pharmaceuticals?

    CORXEL Pharmaceuticals has 45 total employees.

  • What industry is CORXEL Pharmaceuticals in?

    CORXEL Pharmaceuticals’s primary industry is Drug Discovery.

  • Is CORXEL Pharmaceuticals a private or public company?

    CORXEL Pharmaceuticals is a Private company.

  • What is CORXEL Pharmaceuticals’s current revenue?

    The current revenue for CORXEL Pharmaceuticals is .

  • How much funding has CORXEL Pharmaceuticals raised over time?

    CORXEL Pharmaceuticals has raised $452M.

  • Who are CORXEL Pharmaceuticals’s investors?

    Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital (HgC), Invus (Private Equity), and New Enterprise Associates are 5 of 15 investors who have invested in CORXEL Pharmaceuticals.

  • Who are CORXEL Pharmaceuticals’s competitors?

    Zhiyi Biotechnology is a competitor of CORXEL Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process